Foundayo's label establishes the first no-timing-rules oral GLP-1 for weight

The US prescribing information for Foundayo (orforglipron), an oral GLP-1 receptor agonist from Eli Lilly and Company, has been posted on DailyMed, with the label revised 7/2026 and the listing updated July 29, 2026 ^[1]. The label lists an initial US approval year of 2026 ^[1].

Foundayo is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight who also have at least one weight-related comorbid condition ^[1]. Under "Limitations of Use," the label says concomitant use with another GLP-1 receptor agonist is not recommended ^[1].

How the pill is taken

The administration instructions are short. Foundayo is taken orally once daily, with or without food ^[1]. Tablets are swallowed whole and should not be broken, crushed, or chewed, and no more than one tablet a day should be taken ^[1]. The label does not include an instruction to take the tablet on an empty stomach, to use a set amount of water, or to wait a period of time before eating, drinking, or taking other oral medicines. How that compares point-by-point with oral semaglutide's administration instructions is not addressed in this label.

Dosing starts at 0.8 mg once daily, increases to 2.5 mg after at least 30 days, and then to 5.5 mg after at least 30 days on 2.5 mg ^[1]. From there, the dose may be increased to the next level — 9 mg, 14.5 mg, or 17.2 mg once daily — after at least 30 days on the current dose, based on treatment response and tolerability ^[1]. The maximum is 17.2 mg once daily ^[1]. Tablets come in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg strengths ^[1].

Warnings and interactions

Foundayo carries a boxed warning about the risk of thyroid C-cell tumors. The label notes that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, but because it is active at the human GLP-1 receptor, "the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined" ^[1]. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in those with known serious hypersensitivity to orforglipron or its excipients ^[1].

Other warnings include acute pancreatitis, severe gastrointestinal reactions (not recommended in patients with severe gastroparesis), acute kidney injury from volume depletion, hypoglycemia when used with insulin or an insulin secretagogue, serious hypersensitivity reactions, diabetic retinopathy complications in type 2 diabetes, acute gallbladder disease, and pulmonary aspiration during general anesthesia and deep sedation ^[1].

Adverse reactions reported in at least 5% of treated patients are nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation (belching), gastroesophageal reflux disease, flatulence, and hair loss ^[1].

Because orforglipron is a small molecule handled by liver enzymes, the label adds drug-interaction limits that are unusual for this class: the maximum dose is 9 mg once daily with a strong CYP3A4 inhibitor, strong CYP3A4 inhibitors that also inhibit OATP1B should be avoided, strong CYP3A4 inducers should be avoided, and simvastatin should not exceed 20 mg once daily ^[1]. Foundayo also delays gastric emptying and may affect absorption of other oral medicines ^[1].

Why it matters for patients

The practical takeaway is that Foundayo's label sets no food, fluid, or waiting requirements around the daily tablet, which removes a set of timing steps that can make a pill harder to fit into a routine ^[1]. That is a convenience point, not an efficacy claim — the label excerpt available here does not include weight-loss results, so how much weight people lost in trials is not covered by this source.

Two details deserve attention in conversations with a prescriber. First, the label advises females using oral contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting Foundayo and for 30 days after each dose escalation ^[1]. Second, the CYP3A4 and simvastatin limits mean a full medication list matters here in a way it does not for injectable GLP-1s ^[1]. Pregnancy: the label says Foundayo may cause fetal harm and should be discontinued when pregnancy is recognized ^[1]. It is also not recommended in severe hepatic impairment ^[1].

What happens next

The label was revised in July 2026 and posted on DailyMed on July 29, 2026 ^[1]. US launch timing, pricing, insurance coverage, and pharmacy availability are not stated in the label and are not yet known from this source. Suspected side effects can be reported to Eli Lilly at 1-800-545-5979 or to FDA at 1-800-FDA-1088 ^[1].